



1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Androgens Prior Authorization Request Form (Page 1 of 3)

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Delayed puberty [Android, Androxy, Methitest, methyltestosterone, and Testred only]					
<input type="checkbox"/> Gender Identity Disorder					
<input type="checkbox"/> Hypogonadism					
<input type="checkbox"/> Inoperable breast cancer, palliative treatment [Android, Androxy, Methitest, methyltestosterone, and Testred only]					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Continuation of therapy:					
Is this a continuation of testosterone therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Which gender was the patient at birth? (Select from one of the options below)					
<input type="checkbox"/> Female					
<input type="checkbox"/> Male					
Medication History:					
Select the medications the patient has a failure, contraindication, or intolerance to:					
<input type="checkbox"/> Androderm (testosterone patch)					
<input type="checkbox"/> Androgel 1% (testosterone gel)					
<input type="checkbox"/> Androgel 1.62% gel (testosterone gel)					
<input type="checkbox"/> Androgel 1.62% pump (testosterone pump)					
<input type="checkbox"/> Fortesta (testosterone gel)					
<input type="checkbox"/> Testim (testosterone gel)					
Hypogonadism in men:					
Does the patient have a condition that may cause altered sex-hormone binding globulin (SHBG) (e.g., thyroid disorder, HIV disease, liver disorder, diabetes, obesity)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have a history of one of the following: Bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause hypogonadism (e.g., congenital anorchia, Klinefelter's syndrome)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Laboratory information:					
Total testosterone level:					
Does the patient have two pre-treatment serum total testosterone levels less than 280ng/dL (< 9.7 nmol/L) or less than the reference range for the lab? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Calculated free or bioavailable testosterone level:					
Does the patient have one pre-treatment calculated free or bioavailable testosterone level less than 5 ng/dL (< 0.17 nmol/L) or less than the reference range for the lab? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Androgens_Jan_2018

Androgens Prior Authorization Request Form (Page 2 of 3)

Gender Identity Disorder:

Is the patient using hormones to change physical characteristics? Yes No

Does the patient have demonstrable knowledge of what hormones medically can and cannot do and their social benefits and risks? Yes No

Does the patient have a documented real-life experience (living as the other gender) of at least three months prior to the administration of hormone? Yes No

Has the patient had a period of psychotherapy of a duration specified by the mental health professional after the initial evaluation (usually a minimum of three months)? Yes No

Is the patient a female-to-male transsexual? Yes No

Does the patient meet the definition of Gender Identity Disorder characterized by the following? Yes No

- A strong and persistent cross-gender identification (not merely a desire for any perceived cultural advantages of being the other sex)
- Persistent discomfort with his or her sex or sense of inappropriateness in the gender role of that sex
- The disturbance is not concurrent with a physical intersex condition
- The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning
- The transsexual identity has been present persistently for at least two years
- The disorder is not a symptom of another mental disorder or a chromosomal abnormality

Reauthorization:

If this is a reauthorization request, answer the following questions:

Is the patient's follow-up **total serum** testosterone level drawn within the past 6 months for patients new to testosterone therapy, or 12 months for patients continuing testosterone therapy within or below the normal limits of the reporting lab? Yes No

Is the patient's follow-up **total serum** testosterone level drawn within the past 6 months for patients new to testosterone therapy, or 12 months for patients continuing testosterone therapy outside of the upper limits of normal for the reporting lab and the dose has been adjusted? Yes No

Is the patient's follow-up **calculated free or bioavailable** testosterone level drawn within the past 6 months for patients new to testosterone therapy, or 12 months for patients continuing testosterone therapy within or below the normal limits of the reporting lab? Yes No

Is the patient's follow-up **calculated free or bioavailable** testosterone level drawn within the past 6 months for patients new to testosterone therapy, or 12 months for patients continuing testosterone therapy outside of the upper limits of normal for the reporting lab and the dose has been adjusted? Yes No

Does the patient have a condition that may cause altered sex-hormone binding globulin (SHBG) (e.g., thyroid disorder, HIV disease, liver disorder, diabetes, obesity)? Yes No

Quantity limit requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.



1230 US Highway 11

Gouverneur, NY 13642

Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Androgens Prior Authorization Request Form (Page 3 of 3)

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): _____ Date: _____

PROACT INTERNAL USE ONLY:

Clinical Review Decision

Approved, through

Denied (documentation attached, if necessary)

Tracking:

1 st Attempt		2 nd Attempt		Letter Mailed:	
-------------------------	--	-------------------------	--	----------------	--

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Androgens_Jan_2018